Press enter to begin your search
SMSbiotech Leadership Team
Chief Executive Officer; Chairman
30 years of comprehensive operations experience in the medical device field. He was a part of the team who grew Biomet, Inc., which started with a $125,000 loan and was ultimately bought out by a consortium of KKR, Blackstone, TPG and Goldman Sachs for the amount of $11.5 billion.
Richard has tremendous experience from the start-up stage to a multi-billion exit. At Biomet, Rich held key positions such as Vice President of Operations Projects and Strategic Initiatives for eight years as well as Vice President of Manufacturing for 14 years. Biomet specializes in products for knee, hip, and ankle replacements, as well many other products (its product SKU’s exceed 100,000). These specific areas of products and medical procedures are where stem cell therapy products could be applied to enhance healing.
Abdulkader Rahmo, PhD
Co-Founder, President, Chief Scientific Officer
Bachelor in biochemistry from the Swiss Federal institute of Technology (ETH) in Zurich ; PhD in Biochemistry University of Southern California (USC) in Los Angeles and postdoc at a major clinical laboratory in Munich Germany. As a former associate professor he has over 30 years experience in basic and applied research; 11 years primarily focused on SMS cell discovery, development and technology. Experienced in clinical laboratory medicine, GXP compliance and biomanufacturing. Co Founded and lead several private and public entities including the National Commission for Biotechnology where he became the head of the medical Biotechnology section.
Chief Operations Officer
Senior executive with +25 years of experience in implantable devices, wound healing and pharmaceutical markets. Experienced in large companies & startups in US, Europe and Asia. Has Masters in engineering from Tennessee Tech University. Expert in operations & quality management systems.
Over 36 years experience in the Regulatory Affairs; Certified and/or affiliated with more than 15 groups including Regulatory Affairs Certification from RAPS; Retired Lieutenant Colonel US Marines; has worked with SMSbiotech in regulatory for many years.
Prof. James Sherley, MD
Former Associate professor at MIT (nine years), founder and former director of the Adult Stem Cell Technology Center at the Boston Biomedical Research Institute (five years); currently founder and Director of Asymmetrex, LLC, Adjunct Associate Professor, Hematology-Oncology Department, Rhode Island Hospital Brown University.
Prof. Peter Wagner, MD
Emeritus Prof. at UCSD, leader in Respiratory Physiology, served as the Pres. of the American Thoracic Society, Pres. of the American Physiological Society, and Division Chief of both Physiology and Pulmonary Critical Care at UCSD School of Medicine, and as both member and chair of National Institutes of Health study sections.
Roger Schechter, MD
FACEP, FCCWS, UHM-ABEM, Medical Director for Wound Management at Palomar Health San Diego, Chief Medical Officer at Synergy Wound Technology, trained in Emergency Medicine, practices full time as a Wound Care and Hyperbaric Medicine Physician, a national level speaker on wound care, advanced wound care modalities, and non-invasive vascular testing.
Mazen Shihabi, PhD.
Senior Scientist at JPL (Jet Propulsion Laboratory) (eight years), world expert in industrial digital communication experienced in medical device engineering graduate level lecturer at UCI.
Co-founder and CEO of Masimo Corp.
Cofounder and Sr Research Scientist of Masimo Corp.
Serial Entrepreneur, Investor
Partner at Mousavi
and Lee LLP
Partner at Pistone Law Group LLP
error: Content is Property of SMSbiotech